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575Abstracts
Erythomycins/lincosamind/macrolides (49%), Penicillins
(39%), Cephalosporin (9%) and Sulfonamides/Trimetho-
prim (3%). Out of 6 factors explored, only pediatricians
were more likely to prescribe antibiotics for acute bron-
chitis than non-pediatricians (OR = 12.78; 95% CI,
1.42–115.19). CONCLUSIONS: Our study conﬁrms the
dramatic decrease in potentially inappropriate antibiotic
prescribing for children diagnosed with common colds
and URIs. The rate of potentially inappropriate antibiotic
prescribing remained high (79%) for children diagnosed
with bronchitis with the highest rates observed for chil-
dren seeking care from a pediatrician. More than half of
antibiotic classes prescribed for bronchitis were consid-
ered to be ineffective for underlining pathogens in cases
of bacterial bronchitis complications.
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OBJECTIVES: The objective of this health technology
assessment (HTA) commissioned by the German Agency
for HTA/ German Federal Ministry of Health was to
establish an interdisciplinary expert network, to system-
atically review the evidence on effectiveness and cost-
effectiveness of initial antiviral combination therapy for
chronic hepatitis C (CHC) and to apply these data in the
context of the German health care system. METHODS:
A systematic literature review was conducted and study
quality/transferability to the German context were
assessed using standard instruments of the German
Agency for HTA. A decision-analytic Markov model was
developed including pooled short-term outcomes (sus-
tained virological response [SVR] and respective pooled
relative risks) from a recently published Cochrane
Review, single RCTs, utilities from a large German
quality-of-life survey in CHC patients (n = 428), and
German cost data. The model was used to determine
long-term morbidity, life expectancy, and lifetime costs of
different treatment strategies using the societal perspec-
tive. One- and multi-way sensitivity analyses were per-
formed. RESULTS: International clinical studies indicate
that combination therapy with pegylated interferon and
ribavirin (PCOM) achieves highest SVR (54–61%), fol-
lowed by standard combination therapy with interferon
and ribavirin (SCOM) with 37–54%, and interferon
monotherapy (MONO) with 11–21%. Based on interna-
tional cost-effectiveness studies, SCOM is “cost-effective”
compared to MONO. Our decision analysis conﬁrmed
these ﬁndings for the German health care context. No
published articles were available for assessing the cost-
effectiveness of PCOM. Based on our decision analysis,
PCOM dominated SCOM, and its discounted incremen-
tal cost-effectiveness ratio compared to MONO was
€8,200 per quality-adjusted life year. These results were
robust in sensitivity analyses. CONCLUSIONS: This
HTA suggests that initial combination therapy should
prolong life, improve quality-adjusted life expectancy,
and be cost-effective in patients with chronic hepatitis C.
The combination of pegylated interferon and ribavirin is
currently the most effective and efﬁcient antiviral treat-
ment for CHC.
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OBJECTIVES: High coverage is crucial for the success of
vaccination strategies. We investigate the effect of differ-
ent coverage levels of varicella vaccination in Germany
on the possible elimination of varicella, clinical effective-
ness (measured as percentage of preventable varicella
cases prevented), possibility of age-shifts, and economic
outcomes. METHODS: Using an established, age-
structured, decision-analytic model named EVITA 
(Economic Varicella VaccInation Tool for Analysis), 
we analyze the impact of vaccinating children aged 15
months against varicella-zoster-virus. Main assumptions
are: efﬁcacy 86%, costs discounted by 5%, analytic time
horizon 30 yrs. Coverage levels are varied from 0% to
100%. RESULTS: For coverage levels above 75%, vari-
cella can be eliminated within 26.5 years (at 75%), 18
years (at 85%) and 14.5 years (at 100%). At coverage
levels below 30% clinical effectiveness is smaller than the
respective coverage levels, from 40% to 70% clinical
effectiveness is higher than coverage showing the strong
effect of herd immunity. Above 70% clinical effectiveness
remains nearly constant due to the elimination. Because
vaccination is very effective in reducing the number of
cases in young children, the relative proportion of vari-
cella cases of adolescents and adults increases. However,
the total number of cases declines in all age groups for
coverage levels above 50%, i.e. no age-shift occurs. Costs
rise linear with coverage, savings rise even steeper until
70% coverage and remain constant for higher coverage
levels. Therefore, net savings are greatest at coverage
levels of about 70%. Beneﬁt-cost-ratios rise up to cover-
age levels of 70% and fall for coverage higher than 80%.
All beneﬁt-cost-ratios are above 1 showing that net
savings occur from both perspectives the payers’ and the
societal. CONCLUSIONS: Epidemiological considera-
tions favor coverage levels of more than 75% to elimi-
nate varicella and to ensure that no age-shift occurs. From
